目次

1. Research Methodology

2. Global Lung Cancer Antibodies Market Overview
2.1 Current Market Scenario
2.2 Regional Market Analysis
2.3 Future Market Opportunity

3. Global Lung Cancer Antibodies Clinical Trials Overview
3.1 By Company
3.2 By Country
3.3 By Phase
3.4 By Patient Segment

4. Lung Cancer Immune Checkpoint Inhibitors Insight
4.1 Overview
4.2 Drugs Availability, Patent, Price and Dosage Analysis

5. Lung Cancer Monoclonal Antibodies Insight
5.1 Overview
5.2 Drugs Availability, Patent, Price and Dosage Analysis

6. Lung Cancer Bispecific Antibodies Insight
6.1 Overview
6.2 Drugs Availability, Patent, Price and Dosage Analysis

7. Lung Cancer Monoclonal Antibodies - Global and Regional Sales Analysis
7.1 Opdivo
7.2 Keytruda
7.3 Yervoy
7.4 Imfinzi
7.5 Jemperli
7.6 Libtayo
7.7 Tecentriq
7.8 Avastin
7.9 Mvasi
7.10 Zirabev
7.11 Cyramza

8. Global Lung Cancer Antibodies Clinical Pipeline By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-II/III
8.8 Phase-III
8.9 Preregistration
8.10 Registered

9. Marketed Lung Cancer Antibodies Clinical, Patent and Orphan Designation Insight

10. Competitive Landscape
10.1 AbbVie
10.2 Amgen
10.3 AstraZeneca
10.4 BeiGene
10.5 Bristol Myers Squibb
10.6 Eli Lilly
10.7 GlaxoSmithKline
10.8 Innovent
10.9 Janssen Pharmaceuticals
10.10 Merck
10.11 Pfizer
10.12 Roche
10.13 Samsung Bio

List of Figures & Tables
Figure 2-1: Global - Lung Cancer Incidences and Deaths (Million), 2020 and 2030
Figure 2-2: Global - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2018 - 2021
Figure 2-3: Global - Lung Cancer Antibodies Therapeutics Market Size by Region (US$ Billion), 2021
Figure 2-4: Global - Lung Cancer Antibodies Therapeutics Market Size by Region (%), 2021
Figure 2-5: Global - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-6: US - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-7: Europe - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-8: China - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 2-9: Japan - Lung Cancer Antibodies Therapeutics Market Size (US$ Billion), 2022 - 2028
Figure 3-1: Global - Lung Cancer Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-2: Global - Lung Cancer Antibodies in Clinical Trials by Company, 2022 till 2028
Figure 3-3: Global - Lung Cancer Antibodies in Clinical Trials by Phase, 2022 till 2028
Figure 3-4: Global - Lung Cancer Antibodies in Clinical Trials by Patient Segment, 2022 till 2028
Figure 4-1: Opdivo - Approval Year by Region
Figure 4-2: Opdivo - FDA Approval by Indication
Figure 4-3: Opdivo - Patent Expiration Year by Region
Figure 4-4: US - Price for 4ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-5: US - Price for 10 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-6: US - Price for 12 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-7: US - Price for 24 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (US$), May’2022
Figure 4-8: UK - Price for 4 ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-9: UK - Price for 10ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-10: UK - Price for 24ml Supply and Price Per ml of Opdivo 10mg/ml Intravenous Injection (GBP/US$), May’2022
Figure 4-11: Opdivo Monotherapy Therapy - Single Treatment Cycle and Full Treatment Average Cost (US$), May’2022
Figure 4-12: Keytruda - Approval Year by Region
Figure 4-13: Keytruda - FDA Approval Year by Indication
Figure 4-14: Keytruda - Patent Expiration Year by Region
Figure 4-15: US - Price for 4ml, 8ml Supply and Price Per ml of Keytruda Intravenous Injection (US$), May’2022
Figure 4-16: UK - Price for 4ml and Price Per ml of Keytruda 100mg Intravenous Injection (GBP/US$), May’2022
Figure 4-17: Yervoy - Approval Year by Region
Figure 4-18: Yervoy - FDA Approval Year by Indication
Figure 4-19: Yervoy - US and Europe Exclusivity Expiration Year
Figure 4-20: US - Price for 10ml Supply and Price Per ml of Yervoy 5mg/ml Intravenous Injection (US$), May’2022
Figure 4-21: US - Price for 40ml Supply and Price Per ml 5mg/ml Yervoy Intravenous Injection (US$), May’2022
Figure 4-22: UK - Price for 10ml and Price Per ml of Yervoy 50mg Intravenous Injection (GBP/US$), May’2022
Figure 4-23: UK - Price for 40ml and Price Per ml of Yervoy 200mg Intravenous Injection (GBP/US$), May’2022
Figure 4-24: Imfinzi - FDA Approval Year by Indication
Figure 4-25: Imfinzi - Approval Year by Region
Figure 4-26: Imfinzi - FDA Approval and Patent Expiration Year
Figure 4-27: US- Price for a Supply of 2.4ml and Price Per ml of Imfinzi Solution for Injection (US$), May’2022
Figure 4-28: US - Price for a Supply of 10 ml and Price Per ml of Imfinzi Solution for Injection (US$), May’2022
Figure 4-29: UK- Price for a Supply of 2.4ml and Price Per ml of Imfinzi Solution for Injection (GBP/US$), May’2022
Figure 4-30: UK- Price for a Supply of 10ml and Price Per ml of Imfinzi Solution for Injection (GBP/US$), May’2022
Figure 4-31: Imfinzi - Average Cost of Single Treatment Cycle and Full Treatment of NSCLC (US$), May’2022
Figure 4-32: US- Price for a Supply of 10ml and Price Per ml of Jemperli Solution for Injection (US$), May’2022
Figure 4-33: UK- Price for a Supply of 10ml and Price Per ml of Jemperli Solution for Injection (GBP/US$), May’2022
Figure 4-34: Jemperli - Average Dose of Initial 4 Cycles and Subsequent Cycles (mg)
Figure 4-35: Jemperli - Average Cost of Initial 4 Cycles and Subsequent Cycles (US$), May’2022
Figure 4-36: Libtayo - Approval Year by Region
Figure 4-37: Libtayo - FDA Approval Year by Indication
Figure 4-38: US- Price for a Supply of 7ml and Price Per ml of Libtayo Solution for Injection (US$), May’2022
Figure 4-39: UK- Price for a Supply of 7ml and Price Per ml of Libtayo Solution for Injection (GBP/US$), May’2022
Figure 4-40: Libtayo - Cost of Single Treatment Cycle and Annual Treatment Cost (US$), May’2022
Figure 4-41: Tecentriq - Approval Year by Region
Figure 4-42: Tecentriq - FDA Approval Year by Indication
Figure 4-43: US- Price for 14ml Supply and Price Per ml of Tecentriq 840mg/14ml Intravenous Injection (US$), May’2022
Figure 4-44: US - Price for 20ml Supply and Price Per ml of Tecentriq 1200mg/20ml Intravenous Injection (US$), May’2022
Figure 4-45: UK- Price for a Supply of 20ml and Price Per ml of Tecentriq Solution for Injection (GBP/US$), May’2022
Figure 4-46: UK- Price for a Supply of 14ml and Price Per ml of Tecentriq Solution for Injection (GBP/US$), May’2022
Figure 4-47: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 840mg/2 Week Dose (US$), May’2022
Figure 4-48: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1200mg/3 Week Dose (US$), May’2022
Figure 4-49: Tecentriq - Average Cost of Single Treatment Cycle and Annual Treatment using 1680mg/4 Week Dose (US$), May’2022
Figure 4-50: Tyvyt - NMPA Approval by Indication
Figure 4-51: Tislelizumab - NMPA Approval by Indication
Figure 5-1: Avastin - FDA Approval Year by Indication
Figure 5-2: Avastin - Approval Year by Region
Figure 5-3: US- Price for a Supply of 10 and Price for Single 4ml Avastin Solution for Injection (US$), May’2022
Figure 5-4: US - Price for a Supply of 10 and Price for Single 16ml Avastin Solution for Injection (US$), May’2022
Figure 5-5: UK- Price for a Supply of 4ml and Price Per ml of Avastin Solution for Injection (GBP/US$), May’2022
Figure 5-6: UK- Price for a Supply of 16ml and Price Per ml of Avastin Solution for Injection (GBP/US$), May’2022
Figure 5-7: Avastin - Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC (US$), May’2022
Figure 5-8: Mvasi - Approval Year by Region
Figure 5-9: Mvasi - Price for 4ml Supply and Price Per ml of Intravenous Solution (US$), May’2022
Figure 5-10: Mvasi - Price for 16 ml Supply and Price Per Unit of Intravenous Solution (US$), May’2022
Figure 5-11: Mvasi - Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC and Metastatic Cervical Cancer (US$), May’2022
Figure 5-12: US- Price for a Supply of 4ml and Price Per ml of Zirabev Solution for Injection (US$), May’2022
Figure 5-13: US- Price for a Supply of 16ml and Price Per ml of Zirabev Solution for Injection (US$), May’2022
Figure 5-14: UK- Price for a Supply of 16ml, 4ml and Price Per ml of Zirabev Solution for Injection (GBP/US$), May’2022
Figure 5-15: Zirabev - Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC (US$), May’2022
Figure 5-16: UK- Price for a Supply of 4ml and Price Per ml of Aybintio Solution for Injection (GBP/US$), May’2022
Figure 5-17: UK- Price for a Supply of 16ml and Price Per ml of Aybintio Solution for Injection (GBP/US$), May’2022
Figure 5-18: Cyramza - Approval Year by Region
Figure 5-19: US - Cyramza FDA Approval History by Indication
Figure 5-20: US - Cyramza Patent Approval and Expiration Year
Figure 5-21: Cyramza - Patent Exclusivity by Region
Figure 5-22: US - Cost of 10ml and Per unit Price of Cyramza 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-23: US - Cost of 50ml and Per unit Price of Cyramza 10mg/ml Intravenous Solution (US$), May’2022
Figure 5-24: UK- Price for a Supply of 10ml and Price Per ml of Cyramza Solution for Injection (GBP/US$), May’2022
Figure 5-25: UK- Price for a Supply of 50ml and Price Per ml of Cyramza Solution for Injection (GBP/US$), May’2022
Figure 5-26: Cyramza - Cost of Single Treatment Cycle and Annual Treatment Cost for NSCLC (US$), May’2022
Figure 5-27: US - Necitumumab FDA Approval and Patent Exclusivity Year
Figure 5-28: Portrazza - Price for 50ml Supply and Price per unit of 16mg Intravenous Solution (US$), May’2022
Figure 5-29: Portrazza - Minimum Dose and Maximum Dose (in mg)
Figure 6-1: US- Price for 7ml Supply and Price per Unit of Rybrevant 50mg/ml Intravenous Solution (US$), May’2022
Figure 6-2: UK- Price for a 7ml Supply and Price per Unit of Rybrevant 50mg/ml Intravenous Solution (GBP/US$), May’2022
Figure 6-3: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 6-4: Rybrevant - Dose Reduction in Patients with Weight Less Than 80Kg (mg)
Figure 6-5: Rybrevant - Dose Reduction in Patients with Weight More Than 80Kg (mg)
Figure 7-1: Global - Opdivo Sales Value by Region (US$ Million), Q1’2022
Figure 7-2: Global - Opdivo Sales Value by Region (%), Q1’2022
Figure 7-3: Global - Opdivo Sales (US$ Million), 2018-2021
Figure 7-4: US - Opdivo Sales (US$ Million), 2018-2021
Figure 7-5: Global - Opdivo Sales by Region (US$ Million), 2021
Figure 7-6: Global - Opdivo Sales by Region (%), 2021
Figure 7-7: Global - Opdivo Quatery Sales (US$ Million), 2021
Figure 7-8: US - Opdivo Quarterly Sales Value (US$ Million), 2021
Figure 7-9: Global - Opdivo Quarterly Sales (US$ Million), 2020
Figure 7-10: US - Opdivo Quarterly Sales Value (US$ Million), 2020
Figure 7-11: Global - Keytruda Sales (US$ Million), Q1’2021 and Q1’2022
Figure 7-12: Global - Keytruda Sales (US$ Billion), 2018 - 2021
Figure 7-13: Global - Keytruda Quarterly Sales (US$ Billion), 2021
Figure 7-14: Global - Keytruda Quarterly Sales (US$ Billion), 2020
Figure 7-15: Global - Yervoy Sales by Region (US$ Million), Q1’2022
Figure 7-16: Global - Yervoy Sales by Region (%), Q1’2022
Figure 7-17: Global - Yervoy Sales (US$ Million), 2018 - 2021
Figure 7-18: US - Yervoy Sales (US$ Million), 2018 - 2021
Figure 7-19: Yervoy - Sales by Region (US$ Million), 2021
Figure 7-20: Yervoy - Sales by Region (US$ Million), 2021
Figure 7-21: Global - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-22: US - Yervoy Quarterly Sales Value (US$ Million), 2021
Figure 7-23: Global - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-24: US - Yervoy Quarterly Sales Value (US$ Million), 2020
Figure 7-25: Imfinzi -Sales by Region (US$ Million), Q1’2022
Figure 7-26: Imfinzi -Sales by Region (US$ Million), Q1’2022
Figure 7-27: Global - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-28: US - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-29: Europe - Imfinzi Sales (US$ Million), 2019 - 2021
Figure 7-30: Imfinzi - Sales by Region (US$ Million), 2021
Figure 7-31: Imfinzi - Sales by Region (%), 2021
Figure 7-32: Global - Imfinzi Quarterly Sales (US$ Million), 2021
Figure 7-33: US - Imfinzi Quarterly Sales (US$ Million), 2021
Figure 7-34: Global - Imfinzi Quarterly Sales (US$ Million), 2020
Figure 7-35: US - Imfinzi Quarterly Sales (US$ Million), 2020
Figure 7 36: Global - Jemperli Sales by Region (US$/GBP Million), Q1’2022
Figure 7 37: Global - Jemperli Sales by Region (US$/GBP Million), 2021
Figure 7-38: Global - Jemperli Sales by Region (%), 2021
Figure 7-39: US - Jemperli Sales (US$/GBP Million), Q3 and Q4’2021
Figure 7-40: Libtayo -Sales by Region (US$ Million), Q1’2022
Figure 7-41: Libtayo -Sales by Region (%), Q1’2022
Figure 7-42: Global - Libtayo Sales (US$ Million), 2018 - 2021
Figure 7-43: US - Libtayo Sales (US$ Million), 2018 - 2021
Figure 7-44: Libtayo - Sales by Region (US$ Million), 2021
Figure 7-45: Libtayo - Sales by Region (%), 2021
Figure 7-46: Global - Libtayo Quarterly Sales (US$ Million), 2021
Figure 7-47: US - Libtayo Quarterly Sales (US$ Million), 2021
Figure 7-48: Global - Libtayo Quarterly Sales (US$ Million), 2020
Figure 7-49: US - Libtayo Quarterly Sales (US$ Million), 2020
Figure 7-50: Tecentriq -Sales by Region (US$/CHF Million), Q1’2022
Figure 7-51: Tecentriq -Sales by Region (%),Q1’2022
Figure 7-52: Global - Tecentriq Annul Sales (US$/CHF Million), 2019 - 2021
Figure 7-53: US - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-54: Europe - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-55: Japan - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-56: ROW - Tecentriq Sales (US$/CHF Million), 2019 - 2021
Figure 7-57: Tecentriq - Sales by Region (US$/CHF Million), 2021
Figure 7-58: Tecentriq - Sales by Region (%), 2021
Figure 7-59: Global - Tecentriq Quarterly Sales (US$ Billion), 2021
Figure 7-60: US - Tecentriq Quarterly Sales (US$ Billion), 2021
Figure 7-61: US - Tecentriq Quarterly Sales (US$ Million), 2020
Figure 7-62: Avastin -Sales by Region (US$/CHF Million), Q1’2022
Figure 7-63: Avastin -Salesby Region (%), Q1’2022
Figure 7-64: Global - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-65: US - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-66: Europe - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-67: Japan - Avastin Annual Sales(US$/CHF Million), 2019 - 2021
Figure 7-68: ROW - Avastin Sales (US$/CHF Million), 2019 - 2021
Figure 7-69: Avastin - Sales by Region (US$/CHF Million), 2021
Figure 7-70: Avastin - Sales by Region (%), 2021
Figure 7-71: Global - Avastin Quarterly Sales (US$/CHF Million), 2021
Figure 7-72: US - Avastin Quarterly Sales (US$/CHF Million), 2021
Figure 7-73: Mvasi -Sales by Region (US$ Million), Q1’2022
Figure 7-74: Mvasi -Salesby Region (%), Q1’2022
Figure 7-75: Global - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-76: US - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-77: ROW - Mvasi Sales (US$ Million), 2019 - 2021
Figure 7-78: Mvasi -Sales by Region (US$ Million), 2021
Figure 7-79: Mvasi -Sales by Region (%), 2021
Figure 7-80: Global - Mvasi Quarterly Sales (US$ Million), 2021
Figure 7-81: US - Mvasi Quarterly Sales (US$ Million), 2021
Figure 7-82: Global - Mvasi Quarterly Sales (US$ Million), 2020
Figure 7-83: Zirabev -Sales by Region (US$ Million), Q1’2022
Figure 7-84: Zirabev -Sales by Region (%),Q1’2022
Figure 7-85: Global - Zirabev Sales (US$ Million), 2020 and 2021
Figure 7-86: US - Zirabev Sales (US$ Million), 2020 and 2021
Figure 7-87: Zirabev -Sales by Region (US$ Million), 2021
Figure 7-88: Zirabev -Sales by Region (%), 2021
Figure 7-89: Global - Zirabev Quarterly Sales (US$ Million), 2021
Figure 7-90: US - Zirabev Quarterly Sales (US$ Million), 2021
Figure 7-91: US - Zirabev Quarterly Sales (US$ Million), 2020
Figure 7-92: Global - Cyramza Sales (US$ Million), Q1’2021 and Q1’2022
Figure 7-93: Global - Cyramza Sales (US$ Million), 2017 - 2021
Figure 7-94: US - Cyramza Sales (US$ Million), 2017 - 2021
Figure 7-95: Global - Cyramza Sales by Region (US$ Million), 2021
Figure 7-96: Global - Cyramza Sales (%) by Region, 2021
Figure 7-97: Global - Cyramza Sales by Region (US$ Million), 2020
Figure 7-98: Global - Cyramza Sales by Region (%), 2020
Figure 7-99: Global - Cyramza Quarterly Sales (US$ Million), 2021 and 2020